Initial study data indicate GEM103 can regulate complement activity in geographic atrophy secondary to dry age-related macular degeneration and has a tolerable safety profile, according to a press release.
ReGAtta is an ongoing phase 2a multicenter, open-label, multiple ascending dose study evaluating the safety and tolerability of GEM103 (Gemini Therapeutics) in patients with geographic atrophy secondary to dry AMD.
As of May, patients receiving 250 µg or 500 µg intravitreal doses of GEM103 saw sustained, elevated complement factor H levels from the first evaluation point of 1 month, the